cytarabine + daunorubicin + etoposide

Cytarabine + daunorubicin + etoposide, commonly referred to as the "ADE" regimen, is a combination chemotherapy protocol primarily used for the induction treatment of acute myeloid leukemia (AML). Each component has a distinct mechanism of action: - Cytarabine is an antimetabolite that inhibits DNA synthesis by acting as a cytosine analog, leading to cell death in rapidly dividing cells. - Daunorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in DNA strand breaks and apoptosis. - Etoposide is a topoisomerase II inhibitor that causes double-strand DNA breaks by preventing religation of the strands during replication. The ADE regimen exploits these complementary mechanisms to maximize leukemic cell kill. It is most often used as part of intensive induction therapy for newly diagnosed AML patients and may be considered especially in younger adults or those with high-risk disease features. The addition of etoposide to standard cytarabine/daunorubicin regimens has been shown to improve response rates in certain patient populations but can increase toxicity such as mucositis[1][7].

Other names

ADE